Cargando…

Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study

BACKGROUND: Acute kidney injury is a complication of COVID-19 and is associated with severity. Despite no specific antiviral treatment strategy, lopinavir/ritonavir and remdesivir have been used. Data on the association between AKI and receiving antiviral agents with outcomes in hospitalized patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Mousavi Movahed, Seyed Majid, Akhavizadegan, Hamed, Dolatkhani, Fatemeh, Akbarpour, Samaneh, Nejadghaderi, Seyed Aria, Najafi, Morvarid, Pezeshki, Parmida Sadat, Khalili Noushabadi, Akram, Ghasemi, Hoomaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566706/
https://www.ncbi.nlm.nih.gov/pubmed/37819890
http://dx.doi.org/10.1371/journal.pone.0292746
_version_ 1785118968660361216
author Mousavi Movahed, Seyed Majid
Akhavizadegan, Hamed
Dolatkhani, Fatemeh
Akbarpour, Samaneh
Nejadghaderi, Seyed Aria
Najafi, Morvarid
Pezeshki, Parmida Sadat
Khalili Noushabadi, Akram
Ghasemi, Hoomaan
author_facet Mousavi Movahed, Seyed Majid
Akhavizadegan, Hamed
Dolatkhani, Fatemeh
Akbarpour, Samaneh
Nejadghaderi, Seyed Aria
Najafi, Morvarid
Pezeshki, Parmida Sadat
Khalili Noushabadi, Akram
Ghasemi, Hoomaan
author_sort Mousavi Movahed, Seyed Majid
collection PubMed
description BACKGROUND: Acute kidney injury is a complication of COVID-19 and is associated with severity. Despite no specific antiviral treatment strategy, lopinavir/ritonavir and remdesivir have been used. Data on the association between AKI and receiving antiviral agents with outcomes in hospitalized patients with COVID-19 is scarce. We aimed to determine the incidence of AKI and its outcomes in COVID-19 patients with and without antiviral medications. METHODS: We conducted a retrospective study on hospitalized adult patients with SARS-CoV-2 infection in a tertiary center. The primary endpoint was determining mortality, intensive care unit (ICU) admission, and length of hospitalization affected by AKI development using antiviral agents. The logistic regression method was used to explore the predictive effects of AKI and antiviral therapy on composite outcomes (i.e., mortality, ICU admission, and prolonged hospitalization) in four defined groups by AKI development/not and utilizing antivirals/not. We used IBM SPSS version 24.0 software for statistical analysis. RESULTS: Out of 833 COVID-19 patients who were included, 75 patients were treated with antiviral agents and developed AKI. There was a significant difference in the occurrence of AKI and using antiviral medications (p = 0.001). Also, the group using antiviral agents and the development of AKI had the highest rate of preexisting hypertension (p = 0.002). Of note, the group of patients who used antiviral agents and also developed AKI had the most remarkable association with our composite outcome (p<0.0001), especially ICU admission (OR = 15.22; 95% CI: 8.06–27.32). CONCLUSIONS: The presence of AKI among COVID-19 patients treated with antiviral agents is linked to increased severity and mortality. Therefore, it is imperative to explore preventive measures for AKI development in patients receiving antiviral therapy. Larger-scale randomized controlled trials may be warranted to provide a more comprehensive understanding of these associations.
format Online
Article
Text
id pubmed-10566706
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-105667062023-10-12 Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study Mousavi Movahed, Seyed Majid Akhavizadegan, Hamed Dolatkhani, Fatemeh Akbarpour, Samaneh Nejadghaderi, Seyed Aria Najafi, Morvarid Pezeshki, Parmida Sadat Khalili Noushabadi, Akram Ghasemi, Hoomaan PLoS One Research Article BACKGROUND: Acute kidney injury is a complication of COVID-19 and is associated with severity. Despite no specific antiviral treatment strategy, lopinavir/ritonavir and remdesivir have been used. Data on the association between AKI and receiving antiviral agents with outcomes in hospitalized patients with COVID-19 is scarce. We aimed to determine the incidence of AKI and its outcomes in COVID-19 patients with and without antiviral medications. METHODS: We conducted a retrospective study on hospitalized adult patients with SARS-CoV-2 infection in a tertiary center. The primary endpoint was determining mortality, intensive care unit (ICU) admission, and length of hospitalization affected by AKI development using antiviral agents. The logistic regression method was used to explore the predictive effects of AKI and antiviral therapy on composite outcomes (i.e., mortality, ICU admission, and prolonged hospitalization) in four defined groups by AKI development/not and utilizing antivirals/not. We used IBM SPSS version 24.0 software for statistical analysis. RESULTS: Out of 833 COVID-19 patients who were included, 75 patients were treated with antiviral agents and developed AKI. There was a significant difference in the occurrence of AKI and using antiviral medications (p = 0.001). Also, the group using antiviral agents and the development of AKI had the highest rate of preexisting hypertension (p = 0.002). Of note, the group of patients who used antiviral agents and also developed AKI had the most remarkable association with our composite outcome (p<0.0001), especially ICU admission (OR = 15.22; 95% CI: 8.06–27.32). CONCLUSIONS: The presence of AKI among COVID-19 patients treated with antiviral agents is linked to increased severity and mortality. Therefore, it is imperative to explore preventive measures for AKI development in patients receiving antiviral therapy. Larger-scale randomized controlled trials may be warranted to provide a more comprehensive understanding of these associations. Public Library of Science 2023-10-11 /pmc/articles/PMC10566706/ /pubmed/37819890 http://dx.doi.org/10.1371/journal.pone.0292746 Text en © 2023 Mousavi Movahed et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Mousavi Movahed, Seyed Majid
Akhavizadegan, Hamed
Dolatkhani, Fatemeh
Akbarpour, Samaneh
Nejadghaderi, Seyed Aria
Najafi, Morvarid
Pezeshki, Parmida Sadat
Khalili Noushabadi, Akram
Ghasemi, Hoomaan
Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study
title Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study
title_full Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study
title_fullStr Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study
title_full_unstemmed Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study
title_short Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study
title_sort incidence of acute kidney injury (aki) and outcomes in covid-19 patients with and without antiviral medications: a retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566706/
https://www.ncbi.nlm.nih.gov/pubmed/37819890
http://dx.doi.org/10.1371/journal.pone.0292746
work_keys_str_mv AT mousavimovahedseyedmajid incidenceofacutekidneyinjuryakiandoutcomesincovid19patientswithandwithoutantiviralmedicationsaretrospectivestudy
AT akhavizadeganhamed incidenceofacutekidneyinjuryakiandoutcomesincovid19patientswithandwithoutantiviralmedicationsaretrospectivestudy
AT dolatkhanifatemeh incidenceofacutekidneyinjuryakiandoutcomesincovid19patientswithandwithoutantiviralmedicationsaretrospectivestudy
AT akbarpoursamaneh incidenceofacutekidneyinjuryakiandoutcomesincovid19patientswithandwithoutantiviralmedicationsaretrospectivestudy
AT nejadghaderiseyedaria incidenceofacutekidneyinjuryakiandoutcomesincovid19patientswithandwithoutantiviralmedicationsaretrospectivestudy
AT najafimorvarid incidenceofacutekidneyinjuryakiandoutcomesincovid19patientswithandwithoutantiviralmedicationsaretrospectivestudy
AT pezeshkiparmidasadat incidenceofacutekidneyinjuryakiandoutcomesincovid19patientswithandwithoutantiviralmedicationsaretrospectivestudy
AT khalilinoushabadiakram incidenceofacutekidneyinjuryakiandoutcomesincovid19patientswithandwithoutantiviralmedicationsaretrospectivestudy
AT ghasemihoomaan incidenceofacutekidneyinjuryakiandoutcomesincovid19patientswithandwithoutantiviralmedicationsaretrospectivestudy